Ambar Protein Q1 PAT Up 400% To Rs 3.75 Crore Despite Lower Revenue

CONSUMER-PRODUCTS
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Ambar Protein Q1 PAT Up 400% To Rs 3.75 Crore Despite Lower Revenue

Ambar Protein Industries reported a 400% jump in net profit to Rs 3.75 crore for Q1 FY27, even as revenue saw a marginal 3.3% dip. The company also announced its 33rd AGM details.

Ambar Protein Industries Ltd. Reports Strong Profit Growth in Q1 FY27

Ambar Protein's net profit surged by 400% to Rs 3.75 crore in the first quarter ended June 30, 2026, compared to Rs 0.75 crore in the same period last year. Basic EPS rose to Rs 6.53 from Rs 1.30.

Reader Takeaway: Profitability leaps despite revenue dip; AGM to decide on key proposals.

What just happened

Ambar Protein Industries announced its financial results for the first quarter of fiscal year 2027. The company reported a significant increase in net profit, while revenue from operations saw a slight decrease.

Why this matters

The substantial growth in net profit indicates improved operational efficiency or better cost management, which is a positive sign for shareholders. However, the dip in revenue warrants attention.

The backstory

Ambar Protein Industries operates in the protein and edible oil sector. The company's performance typically hinges on raw material prices and demand for its products.

What changes now

Shareholders will be looking closely at the company's strategy to reverse the revenue decline. The proposed resolutions at the AGM, including related party transactions and remuneration changes, will also be crucial.

Risks to watch

The marginal decline in revenue could signal potential market challenges or increased competition.

Peer comparison

(No peer comparison data available in the filing)

Context metrics (time-bound)

Revenue from operations stood at Rs 113.45 crore for Q1 FY27, down from Rs 117.27 crore in Q1 FY26.

What to track next

Investors should closely monitor the outcomes of the 33rd Annual General Meeting (AGM) scheduled for September 30, 2026, particularly the voting on related party transactions and director remuneration. The company's ability to drive revenue growth in upcoming quarters will also be key.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.